Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date of report
(Date of earliest event reported): March 2,
2020
Commission File
Number: 021-214723
AzurRx
BioPharma, Inc.
(Exact name of
registrant as specified in its charter.)
|
Delaware
(State or other
jurisdiction of incorporation or organization)
|
46-4993860
(IRS Employer
Identification No.)
|
760 Parkside Ave., Suite 304, Brooklyn, New York 11226
(Address of principal executive offices)
(Address of principal executive offices)
646-699-7855
(Registrant's Telephone number)
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
(Former Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR
240.12b-2)
Emerging growth
company [ ]
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
Common Stock, par value $0.0001 per share |
Trading Symbol(s)
AZRX |
Name of exchange on which registered
Nasdaq Capital Market |
Item
8.01 Other Events.
On
March 2, 2020, AzurRx BioPharma, Inc. (the "Company") announced
that it has benefited from certain tax credits applicable to French
technology companies through its wholly-owned subsidiary, AzurRx
SAS resulting in a credit of over 1 million Euros in the French
Crédit d’impôt Recherche ("CIR"), a French tax
credit aimed at stimulating research activities. A copy of the
press release is attached hereto as Exhibit 99.1.
This
Current Report on Form 8-K and the exhibit attached hereto may
contain, among other things, certain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including, without limitation, (i) statements with respect
to the Company's plans, objectives, expectations and intentions;
and (ii)other statements identified by words such as "may",
"could", "would", "should", "believes", "expects", "anticipates",
"estimates", "intends", "plans" or similar expressions. These
statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks and
uncertainties.
Exhibit
Index
|
Exhibit No.
|
Description
|
|
|
|
|
Press Release
issued by the Company, dated March 2, 2020.
|
|
|
|
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
AzurRx
BioPharma, Inc.
|
|
|
|
|
Date: March 2, 2020
|
By: /s/ Daniel
Schneiderman
|
|
|
Name: Daniel Schneiderman
|
|
|
Title: Chief Financial Officer
|
|
|
|